From Wikipedia, the free encyclopedia
Jump to: navigation, search
Skeletal formula of cefuroxime
Ball-and-stick model of the cefuroxime molecule
Systematic (IUPAC) name
(6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2Z)-2-(2-furyl)-2-(methoxyimino) acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Zinacef, Ceftin, TURBOCEF
MedlinePlus a601206
  • B
Legal status
  • (Prescription only)
Routes of
intramuscular, intravenous, oral
Pharmacokinetic data
Bioavailability 37% on an empty stomach, up to 52% if taken after food
Biological half-life 80 minutes
Excretion Urine 66–100% unchanged
CAS Registry Number 55268-75-2 YesY
ATC code J01DC02 S01AA27 QJ51DC02
PubChem CID: 5361202
DrugBank DB01112 YesY
ChemSpider 4514699 YesY
KEGG D00262 YesY
Chemical data
Formula C16H16N4O8S
Molecular mass 424.386 g/mol
 YesY (what is this?)  (verify)

Cefuroxime is an enteral or oral second-generation cephalosporin antibiotic. Discovered by the Glaxo company (now GlaxoSmithKline), it was first marketed in 1978 as Zinacef and received approval from the U.S. Food and Drug Administration in October of 1983.[1]

Cefuroxime axetil is an acetoxyetyl-ester-prodrug of cefuroxime which is effective orally.[2]

Medical uses[edit]

As with the other cephalosporins, although as a second-generation variety, it is less susceptible to beta-lactamase. Hence, it may have greater activity against Haemophilus influenzae, Neisseria gonorrhoeae, and Lyme disease. Unlike most other second-generation cephalosporins, cefuroxime can cross the blood-brain barrier.

Side effects[edit]

Cefuroxime is generally well-tolerated and its side effects are usually transient. If ingested after food, this antibiotic is both better absorbed and less likely to cause its most common side effects of diarrhea, nausea, vomiting, headaches/migraines, dizziness, and abdominal pain compared to most antibiotics in its class.[citation needed]

Although a widely stated cross-allergic risk of about 10% exists between cephalosporins and penicillin, recent assessments have shown no increased risk for a cross-allergic reaction for cefuroxime and several other second-generation or later cephalosporins.[3]

Trade names[edit]

The U.S. patent for Cefuroxime has expired. It is sold generically there as Ceftin, and remains available as Zinacef by Covis Pharmaceuticals.[4] It is sold as Supacef by GSK in India,[5] and as Xorimax by Sandoz, Roxibac by RAK Pharmaceuticals Pvt. ltd., Turbocef by Beximco Pharmaceuticals and Furocef (ফিউরোসেফ) by Renata, Kilmax (কিলম্যাক্স)by SK+F Limited, Axet by Orion Pharma Ltd in Bangladesh.

See also[edit]